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Abstract
The identification of MHC class II restricted peptide epitopes is an important goal in immunological research. A number of
computational tools have been developed for this purpose, but there is a lack of large-scale systematic evaluation of their
performance. Herein, we used a comprehensive dataset consisting of more than 10,000 previously unpublished MHC-
peptide binding affinities, 29 peptide/MHC crystal structures, and 664 peptides experimentally tested for CD4+ T cell
responses to systematically evaluate the performances of publicly available MHC class II binding prediction tools. While in
selected instances the best tools were associated with AUC values up to 0.86, in general, class II predictions did not perform
as well as historically noted for class I predictions. It appears that the ability of MHC class II molecules to bind variable length
peptides, which requires the correct assignment of peptide binding cores, is a critical factor limiting the performance of
existing prediction tools. To improve performance, we implemented a consensus prediction approach that combines
methods with top performances. We show that this consensus approach achieved best overall performance. Finally, we
make the large datasets used publicly available as a benchmark to facilitate further development of MHC class II binding
peptide prediction methods.
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Introduction
The activation of CD4+ helper T cells is essential for the
development of adaptive immunity against pathogens [1–4]. A
critical step in CD4+ T cell activation is the recognition of epitopes
presented by MHC class II molecules [5]. MHC class II molecules
are heterodimers expressed on the surface of professional antigen
presenting cells that bind peptide fragments derived from protein
antigens [6]. X-ray crystallographic studies demonstrated that the
MHC class II epitope binding site consists of a groove and several
pockets provided by a b-sheet and two a-helices [7,8]. Unlike class
I, the class II binding groove is open at both ends. As a result,
peptides binding to class II molecules tend to be of variable length,
but typically between 13 and 25 residues.
A hallmark of the MHC class II binding peptide groove is that
there are four major pockets. These pockets accommodate side-
chains of residues 1, 4, 6, and 9 of a 9-mer core region of the
binding peptide. This core region interaction largely determines
binding affinity and specificity [9]. In addition, peptide residues
immediately flanking the core region have been indicated to make
contact with the MHC molecule outside of the binding groove,
and to contribute to MHC-peptide interaction [10].
MHC class II molecules are highly polymorphic, and this
polymorphism largely corresponds with differences along the
peptide binding groove. However, the binding motifs derived for
MHC class II molecules are highly degenerate, and many
promiscuous peptides have been identified that can bind multiple
MHC class II molecules [11]. Promiscuous peptides are a prime
target for vaccine and immunotherapy and computational tools
have been developed to facilitate systematic scanning for
promiscuous peptides [12].
Computational prediction of MHC class II epitopes is of
important theoretical and practical value, as experimental
identification is costly and time consuming [13,14]. The basis of
a successful computational prediction is a sufficiently large set of
high quality training data. There are several databases hosting
MHC epitope related data such as SYFPEITHI [15], MHCBN
[16], Antijen [17], FIMM [18], HLA Ligand [19] and our own
project, the Immune Epitope Database (IEDB) [20,21]. Information
from those databases is, for the most part, extracted from the
literature. These databases typically combine data from different
sources and different experimental approaches, which can compli-
cate the generation of consistent training and evaluation datasets.
The establishment of numerous MHC class II epitope databases
has facilitated the development of a large number of algorithms
aimed at predicting peptide binding to MHC molecules. Early
works focused on finding peptide patterns and deriving motifs for
MHC molecules [22–24]. With the accumulation of epitope data,
more sophisticated algorithms were developed. Several methods
have derived scoring matrices that evaluate the contribution to
binding of different residues in a peptide based on quantitative
binding data (ARB [25], SMM-align [26]). Others base similar
scoring matrices on multiple peptide alignments (RANKPEP
[27,28]) or domain expert knowledge (SYFPEITHI method [15]).
By combining the similarities of key residues forming the pockets
of the binding groove with quantitative matrices derived from
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to MHC alleles for which no binding affinities were determined.
Other machine learning algorithms that have been applied include
hidden Markov models [30], evolutionary algorithms [31] and
linear programming [32]. The MHC class II binding prediction
problem has also been modeled with a distance function in a
recently developed method PepDist [33]. In addition to the
previously listed models that are directly interpretable, ‘‘black
box’’ approaches, such as support vector machines [34] and
artificial neural networks [35–37], have also been applied to MHC
class II binding prediction with success.
Despite the large number of available prediction methods,
computational prediction of MHC class II epitopes remains a
challenging problem. It has been suggested that the prediction
performance of class II algorithms is systematically inferior to that
of MHC class I epitope prediction methods [25]. To assess the
current state of the MHC class II binding predictions, we have
here sought to establish a systematic and quantitative benchmark
similar to our previous effort for MHC class I molecules [38]. We
present a large dataset of unpublished MHC class II-peptide
binding affinities that were experimentally determined under
uniform conditions. We then proceed to evaluate a set of nine
publicly available MHC class II prediction methods using this
dataset and systematically compared their performance. Finally,
we analyzed the ability of current methods to identify the binding
cores of peptides and to predict T-cell responses from peptide
sequences.
Results
Overview of MHC Class II Epitope Affinity Dataset and
MHC Class II Binding Prediction Methods
We assembled a dataset of peptide binding affinities for various
MHC class II molecules experimentally measured in our group
(see Materials and Methods for details). Table 1 gives an overview
of the dataset, encompassing a total of 10,017 experimentally
determined peptide MHC II binding affinities. These data span a
total of 16 human and mouse MHC class II types. The number of
unique MHC-peptide affinities measured per type varies greatly,
from 3,882 for HLA DRB1*0101, to only 39 for H-2-IE
d.
Compared to datasets publicly available on the IEDB and other
MHC class II epitope databases, our new dataset expands the
number of measured peptide-MHC class II interactions signifi-
cantly for a large number of MHC class II molecules. For
example, the number of peptides with known IC50 values for HLA
DRB1*0101 was more than tripled with the addition of our new
dataset.
The MHC class II binding prediction tools evaluated in this
study are listed in Table 2. We included as many prediction
methods as possible provided that they (1) can perform predictions
for MHC class II types in our dataset; (2) were publicly available;
and (3) did not specifically disallow the use of automated
prediction retrieval scripts. A total of nine methods matched these
criteria. A more detailed description of tested methods is provided
in the Materials and Methods section.
Performance Evaluation of Publicly Available Prediction
Tools
The binding predictions for peptides in our affinity dataset were
extracted from the MHC class II binding prediction tools with
custom scripts (see Materials and Methods for details). From the
experimental data, peptides were classified into binders
(IC50,1000 nM) and nonbinders (IC50$1000 nM) based on
measured affinities. The performance of the prediction methods
was then measured by ROC curves (see Materials and Methods
for details). Since the new dataset was never published before, it is
equivalent to a blind test. An important exception is the ARB
method. Since it was developed at IEDB and was constantly
updating with new data, its performance was instead evaluated via
10-fold cross validation.
Table 3 shows the prediction performance of the various
methods in terms of area under ROC curve (AUC). The ROC
curves for tested methods were also plotted in Figure 1 using HLA
DRB1*0101 as an example. SVMHC was not evaluated
Table 1. Overview of the MHC-peptide binding affinity
dataset.
Organism MHC class II types
Number of
MHC-peptide affinities
New Known
a
Human HLA-DRB1*0101 3882 1390
HLA-DRB1*0301 502 817
HLA-DRB1*0401 512 675
HLA-DRB1*0404 449 233
HLA-DRB1*0405 457 175
HLA-DRB1*0701 505 424
HLA-DRB1*0802 245 213
HLA-DRB1*0901 412 174
HLA-DRB1*1101 520 522
HLA-DRB1*1302 289 242
HLA-DRB1*1501 520 491
HLA-DRB3*0101 420 104
HLA-DRB4*0101 245 203
HLA-DRB5*0101 520 383
Mouse H-2-IA
b 500 225
H-2-IE
d 39 231
aNumber of records in IEDB as of 12-04-2006.
doi:10.1371/journal.pcbi.1000048.t001
Author Summary
A critical step in developing immune response against
pathogens is the recognition of antigenic peptides
presented by MHC class II molecules. Since experiments
for MHC class II binding peptide identification are
expensive and time consuming, computational tools have
been developed as fast alternatives but with inferior
performance. Here, we carried out a large-scale systematic
evaluation of existing prediction tools with the aim of
establishing a benchmark for performance comparison
and to identify directions that can further improve
prediction performance. We provide an unbiased ranking
of the performance of publicly available MHC class II
prediction tools and demonstrate that the MHC class II
prediction tools did not perform as well as the MHC class I
tools. In addition, we show that the size of training data
and the correct identification of the binding core are the
two factors limiting the performance of existing tools.
Finally, we make available to the immunology community
a large dataset to facilitate the evaluation and develop-
ment of MHC class II binding prediction tools.
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utilized by PROPRED. When overall performance is assessed by
averaging across all available MHC class II molecules SMM-align
and PROPRED are associated with the best AUC value (0.73).
The ARB method has the third best performance with an average
of AUC of 0.71. When performance on individual MHC class II
molecule is examined, the ARB, PROPRED or SMM-align
perform best for all but the H-2 IEd molecule, for which
RANKPEP gives the best result.
Since we restrict our testing to publicly available tools, it is
important to point out that the methods were trained on different
datasets (Table 2). Some databases such as MHCPEP only include
positive binding data and the lack of nonbinders would be
expected to negatively impact some methods that require negative
training data. Two of the top performing methods (SMM-
align and ARB) utilize the IEDB dataset, confirming that the size
of the training set maybe an important factor contributing to
better performance. PROPRED is among the most accurate
MHC class II binding prediction methods, despite being based
on the TEPITOPE method developed over eight years ago.
The good predictive power of TEPITOPE demonstrates the
validity of its approach, based on pocket information derived
from MHC class II structures and quantitative peptide binding
profiles.
Table 2. Overview of nine MHC class II peptide prediction methods tested with the new dataset.
Category Method MHC class II types
a Training dataset Algorithm
Matrix based ARB 16 (16) IEDB Average relative binding (ARB) matrix
PROPRED 51 (11) TEPITOPE Pocket profile
SVMHC 51 (11) TEPITOPE Pocket profile
SYFPEITHI 6 (6) SYFPEITHI Position specific scoring matrices
RANKPEP 46 (16) MHCPEP Position specific scoring matrices
SMM-align 17 (16) IEDB SYFPEITHI Stabilized matrix
Machine Learning based SVRMHC 6 (5) AntiJen Support vector machine regression
MHC2PRED 21 (15) MHCBN JenPep Support vector machine
Multivariate regression MHCPRED 10 (6) JenPep Quantitative structure activity relationship
(QSAR) regression
aNumber of MHC class II types covered by a prediction method. The number in parentheses is the number of MHC class II types also in our dataset.
doi:10.1371/journal.pcbi.1000048.t002
Table 3. Performance of various MHC class II prediction methods
a.
MHC class II
type
Number of
peptides ARB MHC2PRED MHCPRED PROPRED RANKPEP SMM-align SVRMHC SYFPEITHI Consensus
DRB1*0101 3882 0.76 0.67 0.62 0.74 0.70 0.77 0.69 0.71 0.79
DRB1*0301 502 0.66 0.53 0.65 0.67 0.69 0.65 0.72
DRB1*0401 512 0.67 0.52 0.60 0.69 0.63 0.68 0.66 0.65 0.69
DRB1*0404 449 0.72 0.64 0.79 0.66 0.75 0.80
DRB1*0405 457 0.67 0.51 0.75 0.62 0.69 0.62 0.72
DRB1*0701 505 0.69 0.63 0.78 0.58 0.78 0.68 0.83
DRB1*0802 245 0.74 0.70 0.77 0.75 0.82
DRB1*0901 412 0.62 0.48 0.61 0.66 0.68
DRB1*1101 520 0.73 0.60 0.80 0.70 0.81 0.73 0.80
DRB1*1302 289 0.79 0.54 0.58 0.52 0.69 0.73
DRB1*1501 520 0.7 0.63 0.72 0.62 0.74 0.64 0.67 0.72
DRB3*0101 420 0.59 0.68
DRB4*0101 245 0.74 0.61 0.65 0.71 0.74
DRB5*0101 520 0.7 0.59 0.79 0.73 0.75 0.63 0.79
IAB 500 0.8 0.56 0.51 0.74 0.75 0.86
IED 39 0.53 0.83
Mean 0.71 0.58 0.58 0.73 0.66 0.73 0.65 0.68 0.76
Min 0.59 0.48 0.51 0.58 0.52 0.66 0.62 0.65 0.68
Max 0.8 0.70 0.63 0.80 0.83 0.81 0.69 0.73 0.86
aPerformance is measured in terms of AUC as described in Materials and Methods. Evaluation of ARB was carried out via 10-fold cross validation. Evaluation of the rest of
the methods were done as blind tests.
doi:10.1371/journal.pcbi.1000048.t003
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binders was chosen following an expert immunologist’s recommen-
dation for an immunologically relevant threshold, but it is still
somewhat arbitrary. To further our analysis in a systematic fashion,
we varied the cutoff from 50 nM to 5000 nM. The changes in
cutoffs enable us to evaluate performances of binding prediction to
identify peptides with different affinities. A cutoff of 50 nM focuses
on identifyingstrong binders, while a cutoffof 5000 nM will identify
all including very weak binders. The results of the evaluation using
different cutoffs are shown in Dataset S1. For MHC molecules with
large number of binding affinities (such as HLA DRB1*0101),
varying the cutoff has little impact on the AUC values. For datasets
with smaller number of binding affinities (such as H-2-IE
d), the
change in AUC values is more significant. Despite the variations in
AUC values introduced by different cutoffs, the relative perfor-
manceofdifferentmethodsremainslargelythe same,suggestingour
conclusion of different methods’ performance is not strongly
dependent on the cutoff used to decide binders.
Existing Tools Lack Consistency in Identifying the 9-Mer
Core Interacting with the Binding Groove of the MHC
Class II Molecule
A key difference between MHC class I and class II molecules is
that the binding groove of class II molecules is open at both ends
[7,8]. As a result, the length of peptides binding class II molecules
can vary considerably, and typically range between 13 and 25
amino acids long. Thus, a requisite for all MHC class II binding
prediction approaches is the capacity to identify within longer
sequences the correct 9-mer core residues that mediate the binding
interaction [9]. All methods included in our study explicitly predict
cores when they predict MHC class II binding peptides. They
either predict binders as 9-mer peptides, or clearly state in
prediction the location of the predicted 9-mer core.
We next analyzed whether the various class II prediction tools
can accurately identify the 9-mer cores of a binding peptide. We
extracted MHC-peptide complex structures from the Research
Collaboratory for Structural Bioinformatics (RCSB) Protein Data
Bank (PDB). A total of 29 structures associated with 14 different
MHC class II molecules were identified (Table 4). For each method
we compared the predicted cores with the true cores extracted from
crystal structures. The results are shown in Table 5. The
PROPRED method based on TEPITOPE was associated with
the best performance, with all the predicted cores matching the
coresdetermined byPDB structures.This is ingood agreementwith
the fact that TEPITOPE is directly based on experimental assays.
SYFPEITHI is the second best method with an accuracy of 0.9.
However, this result should be interpreted with caution since seven
of the nine correctly predicted peptides are documented in the
SYFPEITHI database. Apart from PROPRED and SYFPEITHI,
the method most effective in predicting binding affinity (SMM-
align) is also the method with highest accuracy in predicting 9-mers
cores, with an accuracy of 0.625. RANKPEP and SVRMHC come
next with accuracies about 0.55. The remaining three methods had
limited success (21–25%), although they still perform above random
prediction (the probability to randomly guess the right core for a 15-
mer peptide is 1 out of 7 or 0.143). Overall, these data suggest that
correctly aligned cores contribute to the superior performance of
PROPRED and SMM-align, and that there is substantial room to
improve the quality of the core predictions of other methods.
Predicting T Cell Activation from Peptide Sequences with
Existing MHC Class II Epitope Prediction Tools
The ultimate goal of MHC binding peptide prediction is to
identify epitopes that activate T cells. Recognition of a peptide
bound to an MHC molecule by a T cell receptors is the critical
step in this activation, and binding of peptide to the MHC
molecule is obviously a necessary requirement [39]. In a separate
study carried out in our lab, a set of 664 peptides overlapping the
LCMV proteome were tested for their abilities to promote H-2
IA
b specific IFN gamma production from CD4+ T cells in
splenocytes from previously LCMV infected mice (manuscript in
preparation). These peptides provided an ideal test set to evaluate
MHC class II binding predictions as a tool to identify peptides that
trigger an immune response.
For each of the 664 peptides, we obtained H-2 IA
b binding
predictions from the five methods in our study that cover H-2 IA
b
following exactly the same procedures as predictions of simple
binding. We then evaluated the methods’ performance in
predicting which peptides triggered an immune response. The
ROC curves quantifying the performance of each method are
shown in Figure 2. The Consensus method is the best performing
methods with AUC of 0.8960.05. ARB is the second best
performing method with an AUC of 0.8560.05. SMM-align and
RANKPEP have similar performance with AUC about 0.7660.08
and 0.7860.07, respectively. MHCPRED and MHC2PRED do
not perform as well, with AUC values of about 0.6760.12 and
0.3660.1 (standard deviations calculated by bootstrapping with
replacement). Except MHCPRED, every other method’s perfor-
mance in this evaluation compared favourably to that in predicting
peptide binding. Overall, the ranking of prediction performances
is well in concert with that for predicting peptide binding,
specifically when taking into account the high standard deviations
of AUC values. These large standard deviations are due to the
limited number of positive datapoints in the set utilized.
To further analyze the performance of the T cell activation
prediction, we classified peptides into predicted binders and non-
binders. Since different methods produce scores on different scales,
we adopt a rank based classification in that we classify the top 10%
highest scoring peptides as binders. We then calculated sensitivity
and positive predictive value (PPV) for each method (Table 6).
Figure 1. Performance of nine MHC class II prediction methods
using HLA DRB1*0101 as an example. Prediction results for eight
methods for HLA DRB1*0101 are shown in the ROC curve. The curves
were generated by plotting the true positive rate (y-axis) against the
false positive rate (x-axis). The AUC values for corresponding ROC curves
were shown in parentheses.
doi:10.1371/journal.pcbi.1000048.g001
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in identifying T cell activating peptides while minimizing the
number of false positive predictions. In our system, sensitivity is the
percentage of peptides activating T cells predicted to be binders
and PPV is the percentage of predicted binders that actually
activate T cells. The data in Table 6 show that results of these two
measures are largely consistent with the AUC results. Methods
with high AUCs tend to have high PPV and sensitivity. Only the
consensus method has sensitivity above 50%, indicating that 5 out
of 6 methods missed more than half of the T cell activating
peptides when top 10% ranked peptides are classified as binders.
In addition, the consensus method also had the highest PPV value
of 9.4%, making it again the best prediction method by this
measure. The overall low PPV values are expected, as many
peptides that are capable of binding MHC are not recognized by
T cells following a natural infection, due to other factors such as
peptide processing and the available T cell repertoire.
Improving MHC Class II Binding Prediction with a
Consensus Approach
Our evaluation of prediction performance suggests that in all
cases there is clearly room for improvement, and that no single
method is dominantly better than all others. Motivated by the
success of a consensus prediction approach to map MHC class I
epitopes in vaccinia virus [40], we implemented the same
approach for MHC class II binding predictions. This consensus
approach is based on calculating the median rank of the top three
predictive methods for each MHC class II molecule (see materials
and methods for details).
The consensus prediction performance is shown in the last
column of Table 3 for the 14 MHC alleles for which three or more
predictions were available. For ten of these fourteen alleles, the
consensus method gives similar or higher performance than the
best individual method. For each of the remaining four datasets, a
single prediction performs better (i.e., ARB for DRB1*1302,
SMM-align for DRB1*1101 and DRB1*1501, and PROPRED
for DRB1*0405). In terms of overall performance across all
molecules in our dataset, the consensus method outperforms all
individual MHC class II prediction methods.
Availability
The MHC-peptide affinity, MHC-peptide structure and T cell
activation datasets are available as supplemental material at
http://mhcbindingpredictions.immuneepitope.org/MHCII.
Table 4. MHC class II structures used to evaluate the performance of different MHC class II epitope prediction methods.
Core Peptide Chain PDB ID MHC class II type
PFPQPELPY LQPFPQPELPY C 1S9V DQB1*0201
EALYLVCGE LVEALYLVCGERGG C 1JK8 DQB1*0302
LPSTKVSWA EGRDSMNLPSTKVSWAAVGGGGSLVPRGSGGGG C 1UVQ DQB1*0602
MRMATPLLM PVSKMRMATPLLMQA C 1A6A DRB1*0301
FKGEQGPKG AGFKGEQGPKGEPG E 2FSE DRB1*0101
IGILNAAKV GELIGILNAAKVPAD C 1KLG DRB1*0101
VIPMFSALS PEVIPMFSALSEGATP C 1SJE DRB1*0101
WRFLRGYHQ GSDWRFLRGYHQYA C 1AQD DRB1*0101
YSDQATPLL AAYSDQATPLLLSPR C 1T5W DRB1*0101
YVKQNTLKL PKYVKQNTLKLAT C 2G9H DRB1*0101
MRADAAAGG AYMRADAAAGGA E 2SEB DRB1*0401
YVKQNTLKL PKYVKQNTLKLAT C 1J8H DRB1*0401
VHFFKNIVT ENPVVHFFKNIVTPR C 1BX2 DRB1*1501
FKNIVTPRT NPVVHFFKNIVTPRTPPPSQ C 1FV1 DRB5*0101
YHFVKKHVH GGVYHFVKKHVHES C 1H15 DRB5*0101
AQKAKANKA FEAQKAKANKAVDGGGG B 1LNU IA
b
MRMATPLLM GSHSRGLPKPPKPVSKMRMATPLLMQALPMGSGSGS C 1MUJ IA
b
SQAVHAAHA RGISQAVHAAHAEI B 1IAO IA
d
TQGVTAASS GHATQGVTAASSHE B 2IAD IA
d
IAPVFVLLE YEIAPVFVLLEYVT B 1ES0 IA
g7
RHGLDNYRG AMKRHGLDNYRGYS P 1F3J IA
g7
DYGILQINS STDYGILQINSRW P 1IAK IA
k
HRGAIEWEG GNSHRGAIEWEGIESG P 1D9K IA
k
GGASQYRPS HSRGGASQYRPSQRHGTGSGSGS P 1K2D IA
u
IAYLKQASA ADLIAYLKQASAKGG B 1KTD IEK
IAYLKQATK ADLIAYLKQATKGGG B 1KT2 IEK
IAYPKAATK ADLIAYPKAATKF E 1R5V IEK
ITAFNDGLK KKVITAFNDGLKGGG B 1FNE IEK
ITAFNEGLK KKVITAFNEGLKGGG B 1I3R IEK
doi:10.1371/journal.pcbi.1000048.t004
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immunology and bioinformatics community. We are currently in
the process of depositing these data into the IEDB, making them
available through the epitope informatics framework of the IEDB.
Discussion
In this study we have presented a comprehensive dataset for the
systematic evaluation of MHC class II peptide binding prediction
methods. This dataset consists of three components. The first
component is a large set of 10,017 quantitative peptide-binding
affinities for 16 MHC class II types that significantly expands the
amount of publicly available data. These data were generated
under identical experimental conditions and comprise affinities for
binders as well as non-binders. The second component is a set of
non-redundant structures of MHC class II molecules complexed
with peptide ligands compiled from the PDB. This set of structures
provided a ‘‘gold standard’’ for evaluating the ability of prediction
methods to locate the 9-mer core of epitopes. The last component
is a set of 664 peptides that has been tested experimentally to
determine their ability to stimulate CD4+ T cells from widely
utilized C57BL/6 (H-2b) strain of laboratory mice. Together,
these datasets serve as a benchmark set to facilitate the
development and testing of algorithms for predicting peptide
binding to MHC as well as T-cell responses.
Several previous studies have compared the performances of
various MHC class II binding prediction methods [41–43]. The
Borras-Cuesta study [43] from 2000 only had a limited number of
peptides, alleles and methods to compare. The two recent studies
were published after we finished our initial comparison. Gowtha-
man et al [42] compared six commonly used method with data
spanning seven MHC class II alleles. However, their evaluation
dataset comprised only 179 peptides, limiting the significance of
their results. Rajapakse et al [41] compared their multi-objective
evolutionary algorithms (MOEA) with five other algorithm using
two datasets. The first dataset consisted of 1 training and 10 testing
datasets on HLA DRB1*0401 assembled from different sources.
The second dataset was extracted from the IEDB and comprised
more than 5,000 peptides covering 16 MHC class II alleles. We
couldn’t include MOEA in our comparison since it is not publicly
available at the moment. Despite the difference in datasets used in
comparison, their conclusion is consistent with ours in that SMM-
align, TEPITOPE and ARB are the better performing methods.
Figure 2. The performance of various MHC class II binding
prediction approaches to identify CD4+ T cell epitopes. ROC
curves are generated from the predictions made by five MHC class II
peptide binding prediction methods on the LCMV CD4+ T cell
activation data. The AUC value for each method is shown in
parentheses.
doi:10.1371/journal.pcbi.1000048.g002
Table 5. Accuracy of MHC class II prediction methods for identifying epitope core regions.
MHC class II type Known cores Methods (Number of core regions identified correctly)
PROPRED SMM-align RANKPEP ARB MHCPRED MHC2PRED SVRMHC SYFPEITHI
DQB1*0201 1 NA NA 0 NA NA 0 NA NA
DQB1*0302 1 NA NA 0 NA NA 0 NA NA
D Q B 1 * 0 6 0 2 1 N AN A0 N AN AN AN AN A
DRB1*0101 6 6 5541236
DRB1*0301 1 1 110N A 0N A 1
DRB1*0401 2 2 1100201
DRB1*1501 1 1 110N A 011
DRB5*0101 2 2 100N A 02N A
IA
b 2 N A 12000N A N A
IA
d 2 N A 00000N A N A
IA
g7 2 NA NA 0 NA NA 1 NA NA
IA
k 2 N AN A1 N A0 N AN AN A
IA
u 1 NA NA 0 NA NA NA NA NA
IE
k 5 N AN A5 N A3 N AN AN A
Accuracy (Correct/Total) 29 1.000 (12/12) 0.625 (10/16) 0.552 (16/29) 0.250 (4/16) 0.211 (4/19) 0.250 (5/20) 0.545 (6/11) 0.900 (9/10)
doi:10.1371/journal.pcbi.1000048.t005
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existing MHC class II epitope prediction algorithms using these
datasets. Except binding prediction for ARB, all the other MHC
class II prediction algorithms are evaluated in a completely
blinded fashion. In our analysis, the better performing methods
proved to be those that are based on quantitative matrices
extended by method specific features. For example, SMM-align is
the only method tested that considers the contribution of residues
outside of the binding groove, and TEPITOPE is the only method
whose matrices are based on experiments aimed to determine
individual amino acid’s contribution to binding. Merely using
quantitative matrices alone is not sufficient to ensure good
performance, since pure position specific scoring matrix based
methods such as RANKPEP and SYFPEITHI do not perform as
well.
One potential reason for the differential performance of various
methods is the likely different number of data points utilized by the
various methods in the training stage. In this respect, we anticipate
that the datasets described herein, and now made publicly
available, could be utilized to retrain several of the methods and
further increase their performance.
Despite the large number of existing MHC class II epitope
prediction methods, the best performance is generally not as good
as that for MHC class I methods. Indeed, it is notable that the
majority of methods examined in the present study have also been
employed to make predictions for MHC class I peptide binding,
and almost invariably their performance is appreciably better in
the context of class I [38]. For example, when SMM [44] was
applied to predict epitopes for several MHC class I molecules, it
achieved an average AUC of 0.874, which is substantially higher
than that for class II (0.783).
In an attempt to identify what limits the performance of MHC
class II binding prediction, we tested the ability of prediction
methods to identify the 9-mer peptide cores revealed in crystal
structures of MHC-peptide complexes. Except for PROPRED
and SYFPEITHI, the methods examined performed poorly,
suggesting that difficulties in identification the correct binding
core contribute to the inferior performance of class II binding
prediction. It is noteworthy that the two methods with the best
core predictions do not take all positions of a peptide into account
when making binding predictions, but rather focus on anchor
positions in the peptide. This may explain why especially the ARB
method performs much poorer in the core identification rather
than the binding predictions: It treats all positions in the peptide
identically and relies on automated peptide alignments to derive
an overall peptide profile. While this inclusion of weakly
interacting positions can be an advantage to predict overall
peptide binding, it may lower the accuracy when picking the
correct core.
In an attempt to improve upon the prediction performance
realized by individual prediction tools, we implemented a
consensus approach for class II binding predictions. The consensus
approach was found to clearly outperform each individual
prediction approach when measured over the entire dataset, and
provided the best predictions for 10 out of 14 molecules. This
shows that the consensus approach is just as useful for MHC class
II peptide binding prediction as its recent successful application for
MHC class I molecules [40]. In a smaller study addressing 3
different prediction methods in the context of a single DR type,
Mallios previously came to a similar conclusion [45].
Other types of meta approaches have been successfully applied
to MHC binding prediction. For example, Mallios [46] has used
an iterative stepwise discriminant analysis meta-algorithm to
successfully classify binders and non-binders for HLA-DR1. Stern
and co-workers effectively used a two-dimensional dot plot to
combine the prediction results of SYFPEITHI and TEPITOPE
[47]. Finally, Trost et al [48] have reported achieving greater
accuracy in MHC class I binding predictions by combing results
from multiple prediction tools. Compared to these methods, our
median rank approach does not depend on the absolute values of
scores and it has exceptional scalability since typical sorting
algorithms have running times proportional to n log n where n is
the number of cases needed to be sorted. Overall, it is astonishing
that the systematic use of consensus predictions comes rather late
(see Mallios [45,46]) to the problem of MHC peptide binding since
consensus approaches have for quite some time proven their
superiority in a number of fields, notably protein structure
prediction [49].
In any case, it is also likely that the remarkable increase in
performance obtained by the use of the consensus approach hinges
on the fact that it combines information derived from methods
trained on large numbers of data points with methods incorpo-
rating structural considerations leading to effective core predic-
tions. We are currently working on development of algorithms
specifically combining these two different features.
We also tested the ability of MHC class II binding prediction
methods to predict a peptide’s ability to activate CD4+ T cells.
Most of the methods were associated with good performance. This
was somewhat surprising since T cell activation is a multi-step
process where multiple signals are needed for successful activation
[50–52]. In addition, a peptide that binds well to MHC molecules
is not necessarily a good stimulator for T-cell response as different
amino acids are interacting with T cell receptor. It is important to
point out that the performance was based on a set of 664 peptides
of which only 9 activated CD4+ T cells. The limited number of
positive cases makes the ROC curve jagged and the AUC values
calculated less robust. Despite the encouraging AUC values
achieved by several methods, it is still necessary to test a large
number of peptides to identify most of the T cell activating
peptides. In addition, all those methods still have high numbers of
false positives peptides that are predicted binders but will not
activate T cells. Since experimental efforts to test T cell activation
are even more time consuming than testing peptide-MHC
binding, significant efforts are needed to develop tools that can
identify T cell activating peptides with high sensitivity and
specificity.
In conclusion, we have presented a set of benchmarks to
facilitate the evaluation and development of MHC class II binding
Table 6. Sensitivity and positive predictive value for predicting T cell activation.
ARB MHC2PRED MHCPRED RANKPEP SMM-align Consensus
Sensitivity 4/9 (44.4%) 2/9 (22.2%) 1/9 (11.1%) 3/9 (33.3%) 2/9 (22.2%) 6/9 (66.7%)
Positive predictive value 4/64 (6.2%) 2/64 (3.1%) 1/64 (1.6%) 3/64 (4.7%) 2/64 (3.1%) 6/64 (9.4%)
doi:10.1371/journal.pcbi.1000048.t006
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not reach the performance of those for MHC class I molecules.
We have shown that a simple and robust consensus approach can
improve the prediction performance for the great majority of the
MHC class II molecules tested. Finally, we speculate that novel
approaches that capture distinct features of MHC class II peptide
interactions could lead to more successful predictions than the
current approaches, which are commonly developed as extensions
of MHC class I predictions.
Materials and Methods
Peptide Synthesis
Peptides utilized for the assessment of MHC binding,
antigenicity and immunogenicity were purchased as crude
material from Mimotopes (Minneapolis, MN and Clayton,
Victoria, Australia), Pepscan Systems B.V. (Leylstad, Netherlands)
or A and A Labs (San Diego, CA). Quality control analyses of
crude syntheses were performed by mass spectrometry on
randomly selected peptides. Peptides selected for additional
deconvolution and HLA peptide binding assays were resynthesized
by A and A as purified material. Peptides were purified to .95%
by reversed-phase HPLC, and the purity assessed by amino acid
sequence and/or composition analysis.
Experimental Procedures to Measure MHC Class II
Peptide Affinity
Quantitative assays to measure the binding affinities of peptides
to purified soluble class II molecules are based on the inhibition of
binding of a radiolabeled standard peptide. Binding assays were
performed essentially as described previously [13,53]. Briefly, 0.1–
1 nM radiolabeled peptide was coincubated for 2 days at room
temperature with 1 mM to 1 nM purified MHC in the presence of
a cocktail of protease inhibitors. Following a two-day incubation,
the amount of MHC bound labelled peptide was determined by
capturing MHC/peptide complexes on LB3.1 antibody coated
Lumitrac 600 microplates (Greiner Bio-one, Longwood, FL), and
measuring bound cpm using the TopCount microscintillation
counter (Packard Instrument Co., Meriden, CT). Individual
peptides were typically tested in 3 or more independent
experiments for its capacity to inhibit the binding of the
radiolabeled peptide. The concentration of peptide yielding 50%
inhibition of the binding of the radiolabeled peptide was
calculated. Under the conditions used, in which [label],[MHC]
and IC50$[MHC], the measured IC50 values are reasonable
approximations of the true Kd values. The binding affinities are
expressed in terms of IC50 and are capped at 50,000 nM,
reflecting the experimental sensitivity threshold.
Dataset of Binding Affinities Used in the Study
The assembled MHC class II peptide binding affinities are listed
in Table 1. The peptide binding affinities for various MHC class II
molecules were generated in the context of various projects
currently ongoing in our laboratory. Because they have been
recently generated, to the best of our knowledge, none of the
binding affinities in this dataset has been previously published.
This assessment was confirmed by comparing our dataset to
publicly available records contained in the IEDB (Table 1) or
elsewhere. There are total 10,017 measured affinities in our
dataset spanning thirteen human and three mouse MHC class II
types. Peptides for 114 proteins from 30 organisms were
synthesized and tested. While peptide sizes ranged form 9 to 37
amino acids, the vast majority of the measured affinities are for
15-mers (9,632 out of 10,017). The present dataset is currently in
the process of being deposited in the IEDB.
PDB Structures of MHC Class II and Epitope Complexes
Structures of MHC class II were retrieved from the Protein Data
Bank with a keyword search (using keyword ‘‘MHC class II’’). The
retrieved structures were then examined to select complexes have
epitopes with at least 9 amino acids. In addition, the structures were
examined to identify entries with identical MHC and binding
peptide sequences. For duplicated structures of the same MHC and
epitope, we retained the structure with the highest resolution. The
final dataset contains 29 non-redundant structures.
MHC Class II Binding Prediction Tools Evaluated in This
Study
The eight MHC class II binding prediction tools evaluated in
this study are listed in Table 2. Five of the prediction methods are
based on various scoring matrices. The method developed at
IEDB utilizes the Average Relative Binding (ARB) matrix [25].
PROPRED [54] and SVMHC [55] are web servers based on
TEPITOPE’s pocket profile [29]. Both SYFPEITHI [15] and
RANKPEP [28] use position specific matrices. Another matrix
based approach, SMM-align [26], utilizes the stabilized matrix
method (SMM [44]), but introduces a novel step to identify
peptide binding cores, which makes it applicable to MHC class II
predictions. Two of the methods, SVRMHC [56] and
MHC2PRED (http://www.imtech.res.in/raghava/mhc2pred/in-
dex.html), apply support vector machine or support vector
regression to predict epitopes. Finally, MHCPRED is a quanti-
tative structure activity relationship (QSAR) regression based
method [57].Three of the nine methods, ARB, MHC2PRED and
SMM-align, give predictions in terms of the quantitative affinity of
a peptide for a MHC class II molecule. The predictions of the
other six methods are given as a score which is not directly
translatable into an affinity of peptide-MHC binding.
In terms of the number of MHC class II types covered, the two
TEPITOPE based methods (PROPRED and SVMHC) have the
broadest coverage with 51 types, 11 of which also appear in our
dataset. The next most comprehensive method is RANKPEP
which covers 46 types, 16 of which overlap with our dataset. ARB,
MHC2PRED and SMM-align make predictions for about 20
MHC class II types and the majority of the types (15 to 16) also
appear in our dataset. The three remaining methods
(MHCPRED, SVRMHC and SYFPEITHI) have less coverage,
as they only predict peptide binding for 5 to 6 MHC class II types
in our dataset.
Table 2 also lists the dataset used by each method to train their
predictive models. Training on larger sets of data would be
expected to yield better performance when tested on independent
new data. In this context, the IEDB has HLA-DRB1*0101
binding information for 1390 peptides, AntiJen for 730, and
MHCBN for 588. By contrast, SYFPEITHI lists only 42 entries
for HLA-DRB1*0101. Thus the ARB and SMM-align methods
which use data from the IEDB, had access to the largest training
set compared to other methods, while the SYFPEITHI method
had access to the smallest dataset.
MHC Class II Epitope Prediction with External Tools
We identified eight publicly available MHC class II prediction
tools through literature search and the IMGT link list at http://
imgt.cines.fr/textes/IMGTbloc-notes/. For each tool, we mapped
the MHC types for which predictions could be made to the four-
digit HLA nomenclature (e.g., HLA-DRB1*0101). If this mapping
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of the evaluation. For example, HLA-DR4 could refer to HLA-
DRB1*0401, DRB1*0402 etc, which do have distinct binding
specificities.
For the ARB evaluation, the 10-fold cross validation results
stored at IEDB was used to estimate performance since ARB was
trained on datasets overlapping with the one used in this study. For
the other seven tools in the evaluation, we wrote python script
wrappers to automate prediction retrieval. For the SYFPEITHI
prediction, we patched each testing peptide with three Glycine
residues at both ends before we submitted it for prediction. This
was recommended by the creators of SYFPEITHI method to
ensure that all potential binders are presented to the prediction
algorithm. For all other methods, the original testing peptides were
submitted directly for prediction. Peptide sequences were sent to
the web servers one at a time and predictions were extracted from
the server’s response. To assign a single prediction for peptides
longer than nine amino acids in the context of tools predicting the
affinity of 9-mer core binding regions, we took the highest affinity
prediction of all possible 9-mers within the longer peptide as the
prediction result.
Consensus Approach to Predict MHC Class II Binding
Peptides
For each MHC class II molecules whose binding can be
predicted by three or more algorithms, we employed the following
approach to generate a consensus prediction. First, we selected the
top three methods that give the best performance. For each
method, the tested peptides are ranked by their scores with higher
ranks for better binders. For each tested peptide, the three ranks
from different methods are then taken and the median of the three
is calculated. This median rank is taken as the consensus score.
Performance Measure of External Tools
Receiver operating characteristic (ROC) curves [58] were used
to measure the performance of MHC class II binding prediction
tools. For binding assays, the peptides were classified into binders
(experimental IC50,1000 nM) and nonbinders (experimental
IC50$1000 nM), which was determined as a practical cutoff in
a previous study [59]. For CD4+ T cell activation assays, the
peptides were classified into T-cell epitopes (experimental SFC
count$100) or non-epitopes (experimental SFC count ,100). For
a given prediction method and a given cutoff for the predicted
scores, the rate of true positive and false positive predictions can be
calculated. An ROC curve is generated by varying the cutoff from
the highest to the lowest predicted scores, and plotting the true
positive rate against the false positive rate at each cutoff. The area
under ROC curve is a measure of prediction algorithm
performance where 0.5 is random prediction and 1.0 is perfect
prediction. The plotting of ROC curve and calculation of AUC
are all carried out with the ROCR [60] package for R [61].
LCMV Epitope Identification
C57BL/6 (H-2
b) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME), and infected intraperitoneally with
2610
5 PFU of LCMV Armstrong (i.p.). Spleens were harvested
eight days post infection, and IFN-c ELISPOT assays were
performed as previously described [62] using CD4+ T cells
isolated with anti-CD4+ magnetic beads (Miltenyi Biotech Inc.,
Auburn, CA). Experimental values were expressed as the mean net
spots per million CD4+ cells 6SD for each peptide pool or
individual peptide. For the initial screening of the 83 pools,
responses against each pool were considered positive if a) the
number of spot forming cells (SFCs) /10
6 CD4+ T cells exceeded
the absolute value of the mean negative control wells (effectors plus
APCs without peptide) by two-fold, b) the value exceeded 200
SFCs/10
6 CD4+ cells and c) these conditions were met in at least
two replicate independent experiments. Positive pools were
deconvoluted into their eight individual components and tested
again, to determine which individual peptides were responsible for
the pooled IFN-c response. Responses against individual peptides
were considered positive if they exceeded the threshold of the
mean negative control wells (effectors plus APCs without peptide)
by at least 2 standard deviations and exceeded a threshold of 200
SFCs/10
6 CD4+ cells.
Supporting Information
Dataset S1 AUC values for the tested MHC class II binding
prediction methods using different cutoffs. The cutoffs for binders
were varied from 50 nM to 5000 nM.
Found at: doi:10.1371/journal.pcbi.1000048.s001 (0.03 MB XLS)
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